May 8th, 2020:
There was also an increases expression of granzyme A, which suggests improvement in the antiviral function of leronlimab.
__
Sept. 2023 PDF SEC filing:
Combination Therapy Versus Monotherapy.
#2:
We believe that the Company’s best opportunity for cancer approval is with large pharmaceutical company partners and in combination trials with a class of drugs called PD-L1/PD-1 inhibitors.
__
Cancer Therapy Opportunities for Leronlimab
Opportunity: Combination therapy with PD-L1 Inhibitors
The treatment of cancer has been profoundly changed with the use of immune-oncology drugs such as the PD-L1 inhibitors: (1) OPDIVO®, (2) KEYTRUDA®, and (3) TECENTRIQ®
Not only have these drugs proven to be successful in multiple tumor types but they also represent some of the most successful drugs in the market in terms of revenue.
PD-L1/PD-1 inhibitors act to re-engage the immune cells, in the tumor microenvironment, against the tumor. Eventually this response is tempered by immune exhaustion and infiltration of the tumor microenvironment by T-regulatory cells. Recent studies are showing that the response to PD-L1/PD-1 inhibitors, Immune Control Point (ICI) inhibitors, is controlled by inhibitory mechanisms that the body uses to prevent autoimmunity. Pharma has now found ways to extend the anti-tumor activity of these inhibitors by using combination therapies that inhibit the inhibitory mechanisms thereby extending the enhanced immune response against tumors from PD-L1/PD-1 inhibitors.
Combination Therapies Opportunity:
Leronlimab should prove to be a superior ICI treatment alternative.
Pharma has developed drugs to be used in tandem with the PD-L1/PD-1 inhibitors to “release the brake” they applied to these blockbuster drugs. Ipilimumab (CTLA-1)2 and relatlimab (Lag-3)3 act by inhibiting T-effector cell exhaustion and by inhibiting T-regulatory cells. Current available monoclonal antibody medications (MABs) ipilimumab
(Yervoy) and relatlimab (Lag-3) are being used in combination with PD-L1/PD-1 inhibitors to facilitate the inhibitory mechanisms. These drugs have large market potential as Yervoy already generates $1.5 billion in revenue, expected to exceed $2 billion in annual revenue by 2026.
Checkpoint inhibitor therapy has introduced a revolution in contemporary anticancer therapy. It has led to dramatic improvements in patient outcomes and has spawned tremendous research into novel immunomodulatory agents and combination therapy that has changed the trajectory of cancer care 6.
ICI inhibitors represent a significant advance in the management and survival of cancers such as melanoma or non-small cell bronchial carcinoma, however, they can induce unusual side effects, such as hypophysitis 7 resulting in pituitary gland enlargement and pituitary/hypothalamic dysfunction. A study of patients receiving ICI inhibitors found elevated risk of hypophysitis.
In all cases, no patient recovered their previous hormonal function. The mean time of onset was significantly shorter with ipilimumab than other ICIs. ICI-related hypophysitis generate deficits that do not spontaneously recover, even at a distance from the event, meaning patients will require long-term coordinated onco-endocrinological management
8.
Leronlimab would perform the same function as combination ICI inhibitors by inhibiting T-regulatory cell migration, repolarizing macrophages from M2 (pro-inflammatory/pro-tumor) to M1 (effector, anti-tumor). Evidence found in the HIV and Covid trials indicated that Leronlimab reversed T-cell exhaustion, and also increased Granzyme A (the CANCER BULLETS) in CD8 T-cells.
__
"They" ....knew since 2021 LL & or, ICI was the path
Current MOA's are closure on purpose of their actions.
Dec. 2022 Dr. Gluk mentions cold tumors on pg. 98 of Cytodyn Investor Presentation
Some articles mention Granzyme A is a potential Leronlimab MOA.
Today, Cytodyn shareholders control voting
There was also an increases expression of granzyme A, which suggests improvement in the antiviral function of leronlimab.
__
Sept. 2023 PDF SEC filing:
Combination Therapy Versus Monotherapy.
#2:
We believe that the Company’s best opportunity for cancer approval is with large pharmaceutical company partners and in combination trials with a class of drugs called PD-L1/PD-1 inhibitors.
__
Cancer Therapy Opportunities for Leronlimab
Opportunity: Combination therapy with PD-L1 Inhibitors
The treatment of cancer has been profoundly changed with the use of immune-oncology drugs such as the PD-L1 inhibitors: (1) OPDIVO®, (2) KEYTRUDA®, and (3) TECENTRIQ®
Not only have these drugs proven to be successful in multiple tumor types but they also represent some of the most successful drugs in the market in terms of revenue.
PD-L1/PD-1 inhibitors act to re-engage the immune cells, in the tumor microenvironment, against the tumor. Eventually this response is tempered by immune exhaustion and infiltration of the tumor microenvironment by T-regulatory cells. Recent studies are showing that the response to PD-L1/PD-1 inhibitors, Immune Control Point (ICI) inhibitors, is controlled by inhibitory mechanisms that the body uses to prevent autoimmunity. Pharma has now found ways to extend the anti-tumor activity of these inhibitors by using combination therapies that inhibit the inhibitory mechanisms thereby extending the enhanced immune response against tumors from PD-L1/PD-1 inhibitors.
Combination Therapies Opportunity:
Leronlimab should prove to be a superior ICI treatment alternative.
Pharma has developed drugs to be used in tandem with the PD-L1/PD-1 inhibitors to “release the brake” they applied to these blockbuster drugs. Ipilimumab (CTLA-1)2 and relatlimab (Lag-3)3 act by inhibiting T-effector cell exhaustion and by inhibiting T-regulatory cells. Current available monoclonal antibody medications (MABs) ipilimumab
(Yervoy) and relatlimab (Lag-3) are being used in combination with PD-L1/PD-1 inhibitors to facilitate the inhibitory mechanisms. These drugs have large market potential as Yervoy already generates $1.5 billion in revenue, expected to exceed $2 billion in annual revenue by 2026.
Checkpoint inhibitor therapy has introduced a revolution in contemporary anticancer therapy. It has led to dramatic improvements in patient outcomes and has spawned tremendous research into novel immunomodulatory agents and combination therapy that has changed the trajectory of cancer care 6.
ICI inhibitors represent a significant advance in the management and survival of cancers such as melanoma or non-small cell bronchial carcinoma, however, they can induce unusual side effects, such as hypophysitis 7 resulting in pituitary gland enlargement and pituitary/hypothalamic dysfunction. A study of patients receiving ICI inhibitors found elevated risk of hypophysitis.
In all cases, no patient recovered their previous hormonal function. The mean time of onset was significantly shorter with ipilimumab than other ICIs. ICI-related hypophysitis generate deficits that do not spontaneously recover, even at a distance from the event, meaning patients will require long-term coordinated onco-endocrinological management
8.
Leronlimab would perform the same function as combination ICI inhibitors by inhibiting T-regulatory cell migration, repolarizing macrophages from M2 (pro-inflammatory/pro-tumor) to M1 (effector, anti-tumor). Evidence found in the HIV and Covid trials indicated that Leronlimab reversed T-cell exhaustion, and also increased Granzyme A (the CANCER BULLETS) in CD8 T-cells.
__
"They" ....knew since 2021 LL & or, ICI was the path
Current MOA's are closure on purpose of their actions.
Dec. 2022 Dr. Gluk mentions cold tumors on pg. 98 of Cytodyn Investor Presentation
Some articles mention Granzyme A is a potential Leronlimab MOA.
Today, Cytodyn shareholders control voting
6
